Brentuximab vedotin: targeting CD30 as standard in CTCL.
Brentuximab vedotin: targeting CD30 as standard in CTCL.
Oncotarget. 2018 Feb 23;9(15):11887-11888
Authors: Prince HM, Gautam A, Kim YH
PMID: 29552279 [PubMed]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
More News: Cutaneous T cell lymphoma